Baminercept (BG 9924) is an anti-lymphotoxin beta receptor (LTbetaR) IgG fusion protein (LTbetaR-Ig). Baminercept selectively binds to the LTbetaR ligand LTalpha/beta heterotrimer and LIGHT, block the LTbetaR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogrens syndrome (pSS) and rheumatoid arthritis (RA)[1][2].
Molecular Weight:
(93.76 kDa)
Purity:
99.97
CAS Number:
[909110-25-4]
Target:
TNF Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
